Hospital
Edward W Sparrow Hospital Association
Edward W Sparrow Hospital Association was paid $125.88M by Medicaid between Jan 2018 and Dec 2024, across 711 billing codes. Its largest line is 99285, emergency room visit (most serious) — 21% of everything it billed.
33Billing provider infoEDWARD W SPARROW HOSPITAL ASSOCIATION
LANSING, MI 48912
LANSING, MI 48912
33aNPI1073588711assigned 02/17/2006
33bProvider typeSubstance Use Disorder Rehabilitation Hospital Unit
28Total paid$125.88M
24GClaims4,162,433
24DCodes billed711
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RUSSIAN, MISTY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 319,548 | $13.15M | |
| 2019 | 519,210 | $13.34M | |
| 2020 | 512,052 | $14.26M | |
| 2021 | 697,400 | $20.83M | |
| 2022 | 728,255 | $22.51M | |
| 2023 | 748,687 | $22.76M | |
| 2024incomplete | 637,281 | $19.02M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 21% | 71,663 | 64,864 | $26.02M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 13% | 263,887 | 227,559 | $16.59M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 9.9% | 60,029 | 56,082 | $12.40M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.5% | 64,980 | 58,917 | $8.15M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.2% | 43,396 | 38,624 | $4.09M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.5% | 16,976 | 16,393 | $1.95M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.5% | 20,878 | 17,380 | $1.91M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.4% | 16,342 | 15,533 | $1.74M |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.3% | 47,660 | 18,580 | $1.69M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.3% | 52,932 | 48,770 | $1.69M |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 44,069 | 41,497 | $1.65M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.0% | 18,785 | 18,424 | $1.31M |
699 more codes
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.0% | 66,201 | $1.30M |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.0% | 40,015 | $1.27M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 5,707 | $1.24M |
| 59025 | Fetal non-stress test | <1% | 13,579 | $1.24M |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 33,459 | $1.20M |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 2,481 | $1.17M |
| 64493 | <1% | 2,014 | $1.10M | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 11,185 | $1.09M |
| 64483 | <1% | 2,158 | $1.04M | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12,956 | $919K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,954 | $888K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 5,540 | $783K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 60,842 | $727K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 59,759 | $707K |
| 76830 | Ultrasound, transvaginal | <1% | 12,442 | $707K |
| 80061 | Lipid panel | <1% | 61,208 | $666K |
| 64490 | <1% | 1,225 | $611K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 901 | $594K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 30,214 | $584K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,850 | $575K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 14,269 | $571K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 4,853 | $542K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 5,469 | $524K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 2,912 | $513K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,982 | $504K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 23,034 | $470K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 32,080 | $456K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 8,677 | $452K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 5,291 | $449K |
| 70496 | <1% | 2,927 | $444K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 7,306 | $425K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 1,037 | $423K |
| G0378 | Hospital observation service, per hour | <1% | 19,937 | $421K |
| 76801 | <1% | 7,159 | $419K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 44,136 | $414K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 10,530 | $398K |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | <1% | 819 | $394K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 89,252 | $375K |
| 82947 | <1% | 29,241 | $371K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 6,060 | $361K |
| 80053 | Comprehensive metabolic panel | <1% | 178,736 | $354K |
| 20610 | <1% | 2,590 | $354K | |
| 94060 | <1% | 2,411 | $334K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 31,006 | $328K |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 5,242 | $326K |
| 95811 | <1% | 722 | $322K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 6,675 | $319K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 5,678 | $318K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 5,369 | $314K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 553 | $313K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 610 | $293K |
| 93976 | <1% | 5,235 | $291K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 215,335 | $270K |
| 86481 | <1% | 7,345 | $264K | |
| 93971 | <1% | 4,755 | $253K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 33,549 | $247K |
| 97162 | <1% | 5,052 | $240K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 29,547 | $240K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 21,394 | $237K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 23,766 | $233K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 2,053 | $229K |
| Q3014 | Telehealth originating site facility fee | <1% | 15,536 | $228K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,998 | $222K |
| 93970 | <1% | 2,068 | $217K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 1,759 | $217K |
| 76770 | <1% | 3,745 | $208K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 6,547 | $208K |
| 90378 | <1% | 205 | $206K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 2,117 | $204K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 6,096 | $199K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 629 | $195K |
| 90677 | <1% | 1,270 | $191K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | <1% | 330 | $187K |
| 97161 | <1% | 2,601 | $187K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 14,603 | $174K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 57,163 | $173K |
| 90651 | <1% | 1,580 | $169K | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 247 | $163K |
| 81514 | <1% | 945 | $162K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 60,460 | $159K |
| 70491 | <1% | 1,415 | $144K | |
| 86780 | <1% | 26,236 | $144K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 28,210 | $143K |
| 93017 | <1% | 3,122 | $137K | |
| 76536 | <1% | 2,579 | $129K | |
| 82607 | <1% | 27,765 | $128K | |
| 86900 | <1% | 20,426 | $127K | |
| 86803 | <1% | 23,610 | $118K | |
| 76642 | <1% | 3,109 | $114K | |
| 73221 | <1% | 896 | $109K | |
| 72110 | <1% | 4,708 | $108K | |
| 90686 | <1% | 7,288 | $107K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 11,574 | $99K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 944 | $98K |
| 0001A | <1% | 3,471 | $98K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,768 | $97K |
| 10060 | <1% | 1,044 | $92K | |
| 58301 | <1% | 655 | $92K | |
| 84439 | <1% | 33,261 | $91K | |
| 74174 | <1% | 618 | $91K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 54,325 | $88K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 1,907 | $88K |
| 87536 | <1% | 3,169 | $87K | |
| 72141 | <1% | 818 | $87K | |
| 96367 | <1% | 3,257 | $86K | |
| 91320 | <1% | 799 | $83K | |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 4,414 | $81K |
| 82728 | <1% | 19,446 | $80K | |
| 76882 | <1% | 2,216 | $79K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 2,527 | $78K |
| 87653 | <1% | 6,921 | $76K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 7,634 | $76K |
| 77065 | Tomosynthesis, mammo | <1% | 1,837 | $75K |
| 92523 | <1% | 681 | $74K | |
| 73610 | <1% | 6,751 | $74K | |
| 87506 | <1% | 1,073 | $73K | |
| 93225 | <1% | 1,662 | $73K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 28,701 | $72K |
| 19083 | <1% | 96 | $72K | |
| 82652 | <1% | 6,295 | $72K | |
| 93226 | <1% | 2,157 | $70K | |
| 80074 | <1% | 4,514 | $66K | |
| 97165 | <1% | 1,502 | $65K | |
| 73030 | <1% | 6,173 | $64K | |
| 76820 | <1% | 5,937 | $63K | |
| 90832 | Psychotherapy session, about 30 minutes | <1% | 820 | $63K |
| 71250 | <1% | 1,432 | $63K | |
| 87340 | <1% | 17,420 | $62K | |
| 73110 | <1% | 5,104 | $62K | |
| 70486 | <1% | 2,526 | $62K | |
| 85027 | <1% | 35,855 | $60K | |
| 87563 | <1% | 7,163 | $60K | |
| 0002A | <1% | 1,685 | $58K | |
| 73630 | <1% | 7,202 | $58K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,256 | $57K |
| 83550 | <1% | 21,347 | $57K | |
| 87631 | <1% | 7,656 | $56K | |
| 92526 | <1% | 1,357 | $56K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 212 | $54K |
| 43235 | <1% | 156 | $53K | |
| 97116 | <1% | 4,727 | $53K | |
| 84702 | <1% | 18,270 | $53K | |
| 96417 | <1% | 1,530 | $52K | |
| 73564 | <1% | 5,395 | $52K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,153 | $52K |
| 83013 | <1% | 2,659 | $51K | |
| 84207 | <1% | 5,576 | $50K | |
| 74018 | <1% | 5,561 | $50K | |
| 86003 | <1% | 2,569 | $50K | |
| 96415 | <1% | 1,263 | $50K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 10,884 | $49K |
| 84403 | <1% | 5,707 | $49K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 15,061 | $49K |
| 20611 | <1% | 327 | $49K | |
| 73130 | <1% | 6,292 | $48K | |
| 95782 | <1% | 100 | $47K | |
| J1439 | Injection, ferric carboxymaltose, 1 mg | <1% | 98 | $44K |
| 90732 | <1% | 495 | $44K | |
| 83540 | <1% | 22,012 | $43K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,044 | $43K |
| 73562 | <1% | 2,729 | $42K | |
| 93229 | <1% | 306 | $42K | |
| 87077 | <1% | 18,727 | $41K | |
| 97014 | <1% | 5,224 | $40K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 8,824 | $40K |
| 93975 | <1% | 348 | $39K | |
| 83970 | <1% | 3,131 | $37K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 3,270 | $36K |
| 93798 | <1% | 591 | $35K | |
| 73502 | <1% | 3,086 | $34K | |
| 36591 | <1% | 1,126 | $34K | |
| 86360 | <1% | 2,439 | $34K | |
| 86850 | <1% | 20,659 | $34K | |
| 83516 | <1% | 5,875 | $33K | |
| 86762 | <1% | 7,718 | $33K | |
| 76818 | <1% | 566 | $33K | |
| 73560 | <1% | 1,821 | $32K | |
| 90750 | <1% | 416 | $32K | |
| 82670 | <1% | 3,603 | $32K | |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 16 | $31K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | <1% | 59 | $30K |
| 87522 | Neg quan hep c or qual rna | <1% | 2,352 | $30K |
| 87186 | <1% | 14,139 | $30K | |
| 87209 | <1% | 1,700 | $30K | |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 70 | $30K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 7,865 | $29K |
| 83880 | <1% | 11,327 | $29K | |
| 84481 | <1% | 6,022 | $29K | |
| 36430 | <1% | 184 | $28K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 3,935 | $28K |
| 86706 | <1% | 6,573 | $28K | |
| 93351 | <1% | 241 | $28K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,601 | $27K |
| 73140 | <1% | 2,098 | $27K | |
| 87529 | <1% | 1,835 | $27K | |
| 90480 | <1% | 879 | $27K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 9,915 | $27K |
| 83001 | <1% | 4,471 | $26K | |
| 96112 | <1% | 257 | $26K | |
| 82746 | <1% | 6,363 | $26K | |
| 84146 | <1% | 4,187 | $26K | |
| 87177 | <1% | 3,361 | $26K | |
| 81025 | <1% | 9,763 | $26K | |
| 81001 | <1% | 62,871 | $25K | |
| 86704 | <1% | 5,049 | $24K | |
| 82043 | <1% | 13,593 | $24K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 94 | $24K |
| 0004A | <1% | 666 | $24K | |
| 93296 | <1% | 1,402 | $24K | |
| 88307 | <1% | 852 | $23K | |
| 86140 | <1% | 39,883 | $23K | |
| 87480 | <1% | 3,399 | $22K | |
| 87510 | <1% | 3,397 | $22K | |
| 86235 | <1% | 2,478 | $22K | |
| 86038 | <1% | 6,220 | $22K | |
| 90791 | Psychiatric diagnostic evaluation | <1% | 288 | $21K |
| 83735 | <1% | 41,698 | $21K | |
| 74019 | <1% | 1,358 | $21K | |
| 86359 | <1% | 1,902 | $21K | |
| 57454 | <1% | 168 | $20K | |
| 95813 | <1% | 181 | $20K | |
| 0124A | <1% | 749 | $20K | |
| 82570 | <1% | 12,471 | $20K | |
| 58300 | <1% | 1,303 | $20K | |
| 84402 | <1% | 2,422 | $20K | |
| 73590 | <1% | 3,296 | $20K | |
| 90670 | <1% | 1,407 | $20K | |
| 83002 | <1% | 3,301 | $19K | |
| 12001 | <1% | 1,353 | $19K | |
| 84144 | <1% | 2,785 | $19K | |
| 76825 | <1% | 64 | $19K | |
| 87660 | <1% | 2,901 | $18K | |
| 88342 | <1% | 1,249 | $18K | |
| 77336 | <1% | 338 | $18K | |
| 87070 | <1% | 8,288 | $18K | |
| 80076 | <1% | 31,165 | $18K | |
| 86769 | <1% | 1,884 | $18K | |
| 83655 | <1% | 4,089 | $18K | |
| 73090 | <1% | 2,798 | $18K | |
| 74022 | <1% | 2,416 | $18K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,367 | $17K |
| J7323 | Hyaluronan or derivative, euflexxa, for intra-articular injection, per dose | <1% | 197 | $17K |
| 99495 | <1% | 274 | $17K | |
| 71271 | <1% | 281 | $15K | |
| 85610 | <1% | 28,496 | $15K | |
| 74178 | <1% | 105 | $15K | |
| 72040 | <1% | 1,243 | $15K | |
| 87210 | <1% | 12,107 | $15K | |
| 72050 | <1% | 435 | $15K | |
| 90678 | <1% | 59 | $15K | |
| 70498 | <1% | 2,882 | $15K | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 220 | $15K |
| 82784 | <1% | 3,548 | $15K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 4,366 | $14K |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | <1% | 16 | $14K |
| 90746 | <1% | 393 | $14K | |
| 87625 | <1% | 909 | $14K | |
| 82627 | <1% | 2,115 | $14K | |
| 86255 | <1% | 3,332 | $13K | |
| 0054A | <1% | 412 | $13K | |
| 76813 | <1% | 266 | $13K | |
| 80069 | <1% | 4,848 | $13K | |
| 73080 | <1% | 2,007 | $13K | |
| 81003 | <1% | 40,095 | $13K | |
| 72072 | <1% | 529 | $13K | |
| 82105 | <1% | 2,490 | $12K | |
| 71111 | <1% | 734 | $12K | |
| 0011A | <1% | 520 | $12K | |
| 0012A | <1% | 358 | $12K | |
| 86480 | <1% | 529 | $12K | |
| 87481 | <1% | 361 | $12K | |
| 72158 | <1% | 121 | $12K | |
| 99496 | <1% | 207 | $11K | |
| 83020 | <1% | 2,725 | $11K | |
| 86870 | <1% | 256 | $11K | |
| 82950 | <1% | 5,790 | $11K | |
| 72131 | <1% | 263 | $11K | |
| 85652 | <1% | 18,448 | $11K | |
| 73070 | <1% | 1,038 | $11K | |
| 97163 | <1% | 209 | $10K | |
| 90656 | <1% | 586 | $10K | |
| 77334 | <1% | 44 | $10K | |
| 0071A | <1% | 286 | $10K | |
| 74230 | <1% | 157 | $10K | |
| 84425 | <1% | 1,990 | $10K | |
| 86376 | <1% | 2,272 | $10K | |
| 82785 | <1% | 2,150 | $10K | |
| 52000 | <1% | 31 | $10K | |
| 96523 | <1% | 632 | $10K | |
| 86665 | <1% | 1,695 | $10K | |
| Q5103 | Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg | <1% | 19 | $10K |
| 97035 | <1% | 1,858 | $10K | |
| 82533 | <1% | 2,211 | $10K | |
| 0072A | <1% | 260 | $10K | |
| 93270 | <1% | 686 | $9K | |
| 86225 | <1% | 2,266 | $9K | |
| 84480 | <1% | 1,927 | $9K | |
| 73552 | <1% | 1,976 | $9K | |
| 86901 | <1% | 20,143 | $9K | |
| 93298 | <1% | 505 | $9K | |
| 88304 | <1% | 2,238 | $9K | |
| Q9969 | Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose | <1% | 3,304 | $8K |
| 58100 | <1% | 98 | $8K | |
| 84703 | <1% | 33,553 | $8K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 389 | $8K |
| 86696 | <1% | 1,297 | $8K | |
| 86787 | <1% | 1,979 | $8K | |
| 86708 | <1% | 2,373 | $8K | |
| 77080 | <1% | 142 | $8K | |
| 86812 | <1% | 1,039 | $8K | |
| 82248 | <1% | 5,938 | $8K | |
| 82626 | <1% | 844 | $8K | |
| 86200 | <1% | 1,965 | $8K | |
| 73522 | <1% | 495 | $8K | |
| 90675 | <1% | 48 | $8K | |
| 73000 | <1% | 458 | $8K | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 451 | $7K |
| 93880 | <1% | 96 | $7K | |
| 86430 | <1% | 4,147 | $7K | |
| 93308 | <1% | 78 | $7K | |
| 86671 | <1% | 1,178 | $7K | |
| 84550 | <1% | 5,520 | $7K | |
| 95913 | <1% | 27 | $7K | |
| 94762 | <1% | 122 | $7K | |
| 74183 | <1% | 53 | $7K | |
| 93922 | <1% | 654 | $7K | |
| 84410 | <1% | 664 | $7K | |
| 84153 | <1% | 1,203 | $7K | |
| 77072 | <1% | 162 | $7K | |
| 82140 | <1% | 2,785 | $7K | |
| 88112 | <1% | 949 | $7K | |
| 83690 | <1% | 22,622 | $7K | |
| 84165 | <1% | 2,153 | $7K | |
| 97166 | <1% | 135 | $7K | |
| 82565 | <1% | 32,870 | $7K | |
| 87338 | <1% | 1,302 | $7K | |
| 82247 | <1% | 3,995 | $6K | |
| 82962 | <1% | 4,777 | $6K | |
| 86160 | <1% | 1,209 | $6K | |
| 82024 | <1% | 546 | $6K | |
| 72197 | <1% | 25 | $6K | |
| 95819 | <1% | 77 | $6K | |
| 64450 | <1% | 28 | $6K | |
| 87205 | <1% | 6,637 | $6K | |
| 90837 | Psychotherapy session, about an hour | <1% | 81 | $6K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 26 | $6K |
| 11982 | <1% | 61 | $6K | |
| 87040 | <1% | 7,231 | $6K | |
| 43762 | <1% | 42 | $6K | |
| 76000 | <1% | 425 | $6K | |
| 64400 | <1% | 44 | $6K | |
| 83993 | <1% | 1,285 | $6K | |
| 86695 | <1% | 1,303 | $6K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 39 | $6K |
| 86765 | <1% | 1,495 | $6K | |
| 12011 | <1% | 747 | $5K | |
| 80164 | <1% | 1,681 | $5K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 252 | $5K |
| 92611 | <1% | 125 | $5K | |
| 85660 | <1% | 2,325 | $5K | |
| 84156 | <1% | 4,866 | $5K | |
| 82951 | <1% | 1,207 | $5K | |
| 25600 | <1% | 56 | $5K | |
| 84442 | <1% | 1,366 | $5K | |
| 85730 | <1% | 17,857 | $5K | |
| 86709 | <1% | 1,612 | $5K | |
| 11981 | <1% | 102 | $5K | |
| 88341 | <1% | 391 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 121 | $4K |
| 72074 | <1% | 195 | $4K | |
| 73060 | <1% | 1,324 | $4K | |
| 12002 | <1% | 444 | $4K | |
| 72170 | <1% | 770 | $4K | |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 54 | $4K |
| 86664 | <1% | 1,473 | $4K | |
| 95806 | <1% | 52 | $4K | |
| 93925 | <1% | 41 | $4K | |
| 84436 | <1% | 1,711 | $4K | |
| 84100 | <1% | 4,979 | $4K | |
| 84520 | <1% | 27,498 | $4K | |
| 17110 | <1% | 54 | $4K | |
| 86705 | <1% | 1,103 | $4K | |
| 96411 | <1% | 105 | $4K | |
| 84484 | <1% | 33,542 | $4K | |
| 82977 | <1% | 1,781 | $3K | |
| 82550 | <1% | 8,650 | $3K | |
| 0003A | <1% | 101 | $3K | |
| 82150 | <1% | 2,371 | $3K | |
| 86800 | <1% | 720 | $3K | |
| 96127 | <1% | 5,866 | $3K | |
| 81002 | <1% | 3,311 | $3K | |
| 83615 | <1% | 2,407 | $3K | |
| 83605 | <1% | 34,788 | $3K | |
| 83986 | <1% | 2,932 | $3K | |
| 85240 | <1% | 512 | $3K | |
| 87641 | <1% | 333 | $3K | |
| 87517 | <1% | 237 | $3K | |
| 72156 | <1% | 26 | $3K | |
| 80051 | <1% | 22,331 | $3K | |
| 64447 | <1% | 255 | $3K | |
| 84460 | <1% | 2,188 | $3K | |
| 84145 | <1% | 1,989 | $3K | |
| 73660 | <1% | 256 | $3K | |
| 87902 | <1% | 68 | $3K | |
| 84445 | <1% | 135 | $3K | |
| 96111 | <1% | 37 | $3K | |
| 85246 | <1% | 293 | $3K | |
| 97597 | <1% | 36 | $2K | |
| 93280 | <1% | 176 | $2K | |
| 82330 | <1% | 1,775 | $2K | |
| 85045 | <1% | 2,914 | $2K | |
| 84132 | <1% | 5,906 | $2K | |
| 94726 | <1% | 1,731 | $2K | |
| 95700 | <1% | 13 | $2K | |
| C8908 | Magnetic resonance imaging without contrast followed by with contrast, breast; bilateral | <1% | 12 | $2K |
| 87075 | <1% | 1,721 | $2K | |
| 70487 | <1% | 25 | $2K | |
| 70360 | <1% | 692 | $2K | |
| 85379 | <1% | 8,678 | $2K | |
| P9047 | Infusion, albumin (human), 25%, 50 ml | <1% | 31 | $2K |
| 97130 | <1% | 87 | $2K | |
| 29125 | <1% | 409 | $2K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 335 | $2K |
| 83090 | <1% | 469 | $2K | |
| 86037 | <1% | 175 | $2K | |
| 86039 | <1% | 612 | $2K | |
| 87493 | <1% | 254 | $2K | |
| 84450 | <1% | 1,652 | $2K | |
| 77300 | <1% | 17 | $2K | |
| 70544 | <1% | 24 | $2K | |
| 82272 | <1% | 1,543 | $2K | |
| 83498 | <1% | 178 | $2K | |
| 75561 | <1% | 12 | $2K | |
| 87634 | <1% | 108 | $2K | |
| 97803 | <1% | 657 | $2K | |
| 72100 | <1% | 55 | $2K | |
| 87420 | <1% | 776 | $2K | |
| 76885 | <1% | 37 | $2K | |
| 77290 | <1% | 13 | $2K | |
| 29105 | <1% | 30 | $2K | |
| 87581 | <1% | 570 | $2K | |
| 87486 | <1% | 571 | $2K | |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 17 | $2K |
| 99406 | <1% | 105 | $2K | |
| 90716 | <1% | 424 | $2K | |
| 80197 | <1% | 396 | $2K | |
| 82172 | <1% | 202 | $2K | |
| 83010 | <1% | 521 | $1K | |
| 80178 | <1% | 948 | $1K | |
| 90620 | <1% | 55 | $1K | |
| 93291 | <1% | 177 | $1K | |
| 86308 | <1% | 2,197 | $1K | |
| 84080 | <1% | 359 | $1K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 13 | $1K |
| 92610 | <1% | 38 | $1K | |
| 51798 | <1% | 1,239 | $1K | |
| G0008 | Administration of influenza virus vaccine | <1% | 509 | $1K |
| 85576 | <1% | 1,059 | $1K | |
| 75574 | <1% | 12 | $1K | |
| 82803 | <1% | 4,989 | $1K | |
| 85397 | <1% | 126 | $1K | |
| 83520 | <1% | 179 | $1K | |
| 73700 | <1% | 25 | $1K | |
| 97129 | <1% | 90 | $1K | |
| 0121A | <1% | 31 | $1K | |
| 84134 | <1% | 285 | $1K | |
| 93283 | <1% | 73 | $1K | |
| 85018 | <1% | 2,350 | $1K | |
| G0297 | Low dose ct scan (ldct) for lung cancer screening | <1% | 26 | $1K |
| 82948 | <1% | 7,501 | $1K | |
| 84681 | <1% | 170 | $997.13 | |
| 84305 | <1% | 195 | $969.22 | |
| 82952 | <1% | 748 | $964.79 | |
| 85245 | <1% | 125 | $932.46 | |
| 86593 | <1% | 505 | $931.50 | |
| 74420 | <1% | 263 | $903.28 | |
| 84075 | <1% | 730 | $825.95 | |
| 93271 | <1% | 14 | $779.74 | |
| 73565 | <1% | 78 | $778.83 | |
| 86592 | <1% | 465 | $756.61 | |
| 82378 | <1% | 124 | $698.19 | |
| 90694 | <1% | 79 | $694.49 | |
| 73600 | <1% | 176 | $649.66 | |
| 86923 | <1% | 136 | $643.06 | |
| 0051A | <1% | 19 | $638.01 | |
| 0052A | <1% | 18 | $638.01 | |
| 83525 | <1% | 137 | $629.93 | |
| 85613 | <1% | 223 | $622.07 | |
| 86618 | <1% | 133 | $599.40 | |
| 69209 | <1% | 265 | $577.04 | |
| Q0114 | Fern test | <1% | 140 | $570.69 |
| 82010 | <1% | 2,268 | $555.29 | |
| 87521 | Neg quan hep c or qual rna | <1% | 126 | $520.44 |
| 98927 | <1% | 120 | $520.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 29,081 | $499.85 |
| 86304 | <1% | 139 | $487.08 | |
| G0451 | Development testing, with interpretation and report, per standardized instrument form | <1% | 41 | $487.03 |
| 85384 | <1% | 374 | $469.46 | |
| 96161 | <1% | 40 | $462.07 | |
| 0031A | <1% | 12 | $454.20 | |
| 84466 | <1% | 108 | $453.18 | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 2,975 | $446.54 |
| 88302 | <1% | 164 | $424.29 | |
| 97802 | <1% | 77 | $420.00 | |
| 77073 | <1% | 54 | $414.91 | |
| 94010 | <1% | 57 | $406.53 | |
| 72081 | <1% | 13 | $392.94 | |
| 97760 | <1% | 14 | $389.42 | |
| 86735 | <1% | 99 | $381.91 | |
| 81511 | <1% | 13 | $381.81 | |
| 93299 | <1% | 21 | $376.80 | |
| 73620 | <1% | 68 | $374.96 | |
| 87593 | <1% | 15 | $370.89 | |
| 85390 | <1% | 65 | $369.29 | |
| 0081A | <1% | 13 | $360.72 | |
| 83930 | <1% | 1,406 | $350.38 | |
| 86231 | <1% | 34 | $348.26 | |
| 90734 | <1% | 534 | $343.36 | |
| 82103 | <1% | 135 | $331.58 | |
| 84432 | <1% | 43 | $304.95 | |
| 84630 | <1% | 82 | $276.58 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 68 | $270.25 |
| 82390 | <1% | 93 | $266.96 | |
| 80177 | <1% | 93 | $257.21 | |
| 86147 | <1% | 53 | $251.66 | |
| 87498 | <1% | 38 | $241.30 | |
| 72202 | <1% | 27 | $234.42 | |
| 86632 | <1% | 32 | $233.51 | |
| 86141 | <1% | 55 | $232.82 | |
| 72220 | <1% | 27 | $221.13 | |
| 86631 | <1% | 32 | $219.95 | |
| 76870 | <1% | 1,507 | $207.49 | |
| 82800 | <1% | 2,862 | $206.84 | |
| 83521 | <1% | 24 | $206.03 | |
| 96376 | <1% | 10,561 | $205.80 | |
| 90662 | <1% | 13 | $202.70 | |
| 84155 | <1% | 337 | $191.42 | |
| 84295 | <1% | 4,932 | $187.83 | |
| 90688 | <1% | 21 | $170.39 | |
| 82656 | <1% | 40 | $170.37 | |
| 86644 | <1% | 66 | $167.78 | |
| 87181 | <1% | 25 | $150.59 | |
| 90474 | <1% | 12 | $148.23 | |
| 73100 | <1% | 25 | $144.02 | |
| 84446 | <1% | 38 | $140.56 | |
| 85049 | <1% | 1,029 | $136.33 | |
| 87279 | <1% | 73 | $129.54 | |
| 84590 | <1% | 40 | $124.96 | |
| 93282 | <1% | 12 | $120.36 | |
| 98926 | <1% | 52 | $108.16 | |
| 83921 | <1% | 25 | $103.41 | |
| 88142 | <1% | 80 | $101.54 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,545 | $91.13 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,520 | $89.35 |
| 82435 | <1% | 4,805 | $86.97 | |
| 86431 | <1% | 32 | $78.31 | |
| 87425 | <1% | 69 | $70.85 | |
| 82040 | <1% | 51 | $63.70 | |
| 80202 | <1% | 48 | $60.69 | |
| 86256 | <1% | 12 | $59.44 | |
| 83874 | <1% | 104 | $58.96 | |
| 82180 | <1% | 25 | $57.61 | |
| 69210 | <1% | 14 | $54.34 | |
| 90715 | <1% | 8,280 | $54.16 | |
| J0736 | Injection, clindamycin phosphate, 300 mg | <1% | 69 | $53.51 |
| Q0245 | Injection, bamlanivimab and etesevimab, 2100 mg | <1% | 246 | $52.06 |
| 86580 | <1% | 28 | $49.88 | |
| 82365 | <1% | 64 | $48.25 | |
| 82672 | <1% | 13 | $45.40 | |
| 84478 | <1% | 37 | $44.38 | |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | <1% | 13 | $39.34 |
| 86645 | <1% | 13 | $38.58 | |
| 86677 | <1% | 16 | $33.30 | |
| 85014 | <1% | 1,427 | $33.26 | |
| 87102 | <1% | 24 | $32.05 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 12,611 | $26.05 |
| 85007 | <1% | 113 | $25.92 | |
| 88300 | <1% | 129 | $21.46 | |
| 87184 | <1% | 14 | $20.16 | |
| 86777 | <1% | 13 | $18.64 | |
| 88313 | <1% | 31 | $16.19 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 2,460 | $15.88 |
| 82465 | <1% | 28 | $14.47 | |
| 82374 | <1% | 2,707 | $11.60 | |
| 80299 | <1% | 14 | $10.20 | |
| 82274 | <1% | 16 | $8.96 | |
| 91312 | <1% | 789 | $8.44 | |
| Q0247 | Injection, sotrovimab, 500 mg | <1% | 27 | $4.14 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 17 | $2.54 |
| J1836 | Injection, metronidazole, 10 mg | <1% | 12 | $2.13 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,750 | $1.77 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 67 | $1.20 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 2,485 | $1.07 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,371 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 2,095 | $0.00 |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 0% | 3,509 | $0.00 |
| 99152 | 0% | 5,784 | $0.00 | |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 637 | $0.00 |
| 64491 | 0% | 1,020 | $0.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 3,033 | $0.00 |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 781 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 706 | $0.00 |
| 88173 | 0% | 14 | $0.00 | |
| 90707 | 0% | 426 | $0.00 | |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 2,962 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 8,624 | $0.00 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 0% | 2,048 | $0.00 |
| 94729 | 0% | 1,457 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 763 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 1,748 | $0.00 |
| 90648 | 0% | 1,423 | $0.00 | |
| A9578 | Injection, gadobenate dimeglumine (multihance multipack), per ml | 0% | 4,178 | $0.00 |
| J1756 | Injection, iron sucrose, 1 mg | 0% | 278 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 91 | $0.00 |
| 64495 | 0% | 1,685 | $0.00 | |
| 90633 | 0% | 847 | $0.00 | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 0% | 247 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 743 | $0.00 |
| 76827 | 0% | 51 | $0.00 | |
| J7510 | Prednisolone oral, per 5 mg | 0% | 48 | $0.00 |
| 90681 | 0% | 207 | $0.00 | |
| 90461 | 0% | 1,268 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 378 | $0.00 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | 0% | 12 | $0.00 |
| 93325 | 0% | 120 | $0.00 | |
| 90700 | 0% | 351 | $0.00 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 166 | $0.00 |
| 91308 | 0% | 44 | $0.00 | |
| J0737 | Injection, clindamycin phosphate (baxter), not therapeutically equivalent to j0736, 300 mg | 0% | 26 | $0.00 |
| Q9956 | Injection, octafluoropropane microspheres, per ml | 0% | 155 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 59 | $0.00 |
| C1729 | Catheter, drainage | 0% | 110 | $0.00 |
| 90710 | 0% | 53 | $0.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 15 | $0.00 |
| 84163 | 0% | 13 | $0.00 | |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 60 | $0.00 |
| A4565 | Slings | 0% | 28 | $0.00 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 12 | $0.00 |
| 82731 | 0% | 14 | $0.00 | |
| 82375 | 0% | 15 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 33 | $0.00 |
| G0444 | Annual depression screening, 5 to 15 minutes | 0% | 36 | $0.00 |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | 0% | 17 | $0.00 |
| 99151 | 0% | 13 | $0.00 | |
| A9541 | Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries | 0% | 14 | $0.00 |
| 90696 | 0% | 140 | $0.00 | |
| C1769 | Guide wire | 0% | 1,850 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 1,174 | $0.00 |
| C9290 | Injection, bupivacaine liposome, 1 mg | 0% | 1,499 | $0.00 |
| 94760 | 0% | 2,600 | $0.00 | |
| 90680 | 0% | 613 | $0.00 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 1,963 | $0.00 |
| J3480 | Injection, potassium chloride, per 2 meq | 0% | 697 | $0.00 |
| 90723 | 0% | 1,144 | $0.00 | |
| 64484 | 0% | 1,781 | $0.00 | |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 713 | $0.00 |
| 64492 | 0% | 912 | $0.00 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 119 | $0.00 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 0% | 1,337 | $0.00 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | 0% | 220 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 2,056 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 364 | $0.00 |
| J1815 | Injection, insulin, per 5 units | 0% | 298 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 353 | $0.00 |
| 95886 | 0% | 988 | $0.00 | |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 759 | $0.00 |
| 64494 | 0% | 1,876 | $0.00 | |
| A4648 | Tissue marker, implantable, any type, each | 0% | 263 | $0.00 |
| 99459 | 0% | 774 | $0.00 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | 0% | 150 | $0.00 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | 0% | 635 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 42 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 15 | $0.00 |
| 91307 | 0% | 17 | $0.00 | |
| 96368 | 0% | 460 | $0.00 | |
| 64415 | 0% | 53 | $0.00 | |
| 81015 | 0% | 424 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 198 | $0.00 |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 259 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 103 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 998 | $0.00 |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 0% | 155 | $0.00 |
| C1773 | Retrieval device, insertable (used to retrieve fractured medical devices) | 0% | 29 | $0.00 |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 411 | $0.00 |
| J3490 | Unclassified drugs | 0% | 42 | $0.00 |
| 91305 | 0% | 146 | $0.00 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 163 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 213 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 24 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 12 | $0.00 |
| J0461 | Injection, atropine sulfate, 0.01 mg | 0% | 52 | $0.00 |
| 80050 | General health panel | 0% | 18 | $0.00 |
| 64445 | 0% | 12 | $0.00 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 14 | $0.00 |
| Q0164 | Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 19 | $0.00 |
| C2617 | Stent, non-coronary, temporary, without delivery system | 0% | 47 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 16 | $0.00 |
| C1778 | Lead, neurostimulator (implantable) | 0% | 12 | $0.00 |
| 90647 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRUSSIAN, MISTY (SUPERVISOR, PROVIDER ENROLLMENT)
Parent organizationSPARROW HEALTH SYSTEM
| Provider | Location | Paid |
|---|---|---|
| Metropolitan Hospital | Wyoming, MI | $100.96M |
| Sparrow Ionia Hospital | Ionia, MI | $13.76M |
| Sparrow Eaton Hospital | Charlotte, MI | $13.22M |
| Sparrow Clinton Hospital | Saint Johns, MI | $8.68M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $5.81M |
| Sparrow Carson Hospital | Carson City, MI | $5.48M |
| Edward W. Sparrow Hospital Association | East Lansing, MI | $5.43M |
| Sparrow Ionia Hospital | Ionia, MI | $3.49M |
| Sparrow Eaton Hospital | Charlotte, MI | $3.12M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $2.77M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $2.61M |
| Edward W Sparrow Hospital Association | Lansing, MI | $2.48M |
| Edward W. Sparrow Hospital Association | Mason, MI | $2.44M |
| Sparrow Community Care | Lansing, MI | $2.31M |
| Edward W Sparrow Hospital Association | Lansing, MI | $2.31M |
| Edward W Sparrow Hospital Association | Lansing, MI | $1.85M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $1.83M |
| Edward W. Sparrow Hospital Association | Lansing, MI | $1.65M |
| Sparrow Ionia Hospital | Portland, MI | $1.61M |
| Sparrow Carson Hospital | Ithaca, MI | $1.54M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.